Pub Date : 2026-02-01DOI: 10.1016/s2214-109x(25)00499-1
Francesco Di Gennaro,Luigi Pisani,Giacomo Guido,Annalisa Saracino
{"title":"Proximity as core to co-design in global health.","authors":"Francesco Di Gennaro,Luigi Pisani,Giacomo Guido,Annalisa Saracino","doi":"10.1016/s2214-109x(25)00499-1","DOIUrl":"https://doi.org/10.1016/s2214-109x(25)00499-1","url":null,"abstract":"","PeriodicalId":48783,"journal":{"name":"Lancet Global Health","volume":"264 1","pages":"e197"},"PeriodicalIF":34.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145947468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/s2214-109x(25)00480-2
Pryanka Relan,Jamie Rylance,Yaseen M Arabi,Pauline Convocar,Matthieu Rolland,Janet V Diaz,
BACKGROUNDThe COVID-19 pandemic highlighted a global shortage of, and inequity of access to, medical oxygen. Understanding patient outcomes and the capacities of health facilities to provide respiratory support including oxygen is key to matching need and demand. We report results from a global study including 23 low-income and middle-income countries.METHODSFor this prospective, observational cohort study, consecutive patients aged 12 years or older with suspected or confirmed COVID-19 and evidence of respiratory distress were prospectively recruited within 24 h of hospital admission. Hospitals from 23 low-income and middle-income countries were included, representing all WHO regions. Baseline demographic and clinical data were collected, and daily follow-ups were recorded for in-hospital outcomes and respiratory support types. At the facility level, we assessed sources of oxygen and electricity, infrastructural and staffing capacity for critical care provision, and the capabilities of the facility for advanced respiratory support. The primary outcome was 30-day in-hospital mortality. This study was registered on ClinicalTrials.gov (NCT04918875).FINDINGSBetween Jan 24 and Nov 22, 2022, 56 sites took part. Of 53 726 patients screened, 3070 were enrolled. 1814 (61·6%) of 2947 patients had two or more underlying medical conditions and initially received oxygen through nasal cannula or non-rebreather face masks with reservoir. Invasive mechanical ventilation was most frequently used in patients recruited in the Americas (75 [26·4%] of 284 patients) and in the Eastern Mediterranean (90 [18·0%] of 499 patients). The overall mortality was 649 (23·4%) of 2779 patients, varying by region from 53 (10·5%) of 506 patients in South-East Asia to 286 (37·6%) of 760 patients in Africa. Mortality was associated with the maximum level of respiratory support received: from 17 (8·6%) of 198 patients who received no oxygen, 99 (38·4%) of 258 patients for non-rebreather reservoir bags, and 205 (62·9%) of 326 for invasive ventilation.INTERPRETATIONThe availability and use of oxygen support options in low-income and middle-income countries are highly variable but appear significantly less in the African region. Mortality might be associated with a lack of access to oxygen, which varied across WHO regions but was highest in Africa. Despite many lessons learned from the COVID-19 pandemic, inequity in access to medical oxygen remains a challenge that WHO and partners must address in the post-pandemic era to avoid preventable deaths.FUNDINGUNITAID.
{"title":"Medical oxygen and respiratory support requirements for patients hospitalised with COVID-19 in 23 low-income and middle-income countries: a prospective, observational cohort study.","authors":"Pryanka Relan,Jamie Rylance,Yaseen M Arabi,Pauline Convocar,Matthieu Rolland,Janet V Diaz, ","doi":"10.1016/s2214-109x(25)00480-2","DOIUrl":"https://doi.org/10.1016/s2214-109x(25)00480-2","url":null,"abstract":"BACKGROUNDThe COVID-19 pandemic highlighted a global shortage of, and inequity of access to, medical oxygen. Understanding patient outcomes and the capacities of health facilities to provide respiratory support including oxygen is key to matching need and demand. We report results from a global study including 23 low-income and middle-income countries.METHODSFor this prospective, observational cohort study, consecutive patients aged 12 years or older with suspected or confirmed COVID-19 and evidence of respiratory distress were prospectively recruited within 24 h of hospital admission. Hospitals from 23 low-income and middle-income countries were included, representing all WHO regions. Baseline demographic and clinical data were collected, and daily follow-ups were recorded for in-hospital outcomes and respiratory support types. At the facility level, we assessed sources of oxygen and electricity, infrastructural and staffing capacity for critical care provision, and the capabilities of the facility for advanced respiratory support. The primary outcome was 30-day in-hospital mortality. This study was registered on ClinicalTrials.gov (NCT04918875).FINDINGSBetween Jan 24 and Nov 22, 2022, 56 sites took part. Of 53 726 patients screened, 3070 were enrolled. 1814 (61·6%) of 2947 patients had two or more underlying medical conditions and initially received oxygen through nasal cannula or non-rebreather face masks with reservoir. Invasive mechanical ventilation was most frequently used in patients recruited in the Americas (75 [26·4%] of 284 patients) and in the Eastern Mediterranean (90 [18·0%] of 499 patients). The overall mortality was 649 (23·4%) of 2779 patients, varying by region from 53 (10·5%) of 506 patients in South-East Asia to 286 (37·6%) of 760 patients in Africa. Mortality was associated with the maximum level of respiratory support received: from 17 (8·6%) of 198 patients who received no oxygen, 99 (38·4%) of 258 patients for non-rebreather reservoir bags, and 205 (62·9%) of 326 for invasive ventilation.INTERPRETATIONThe availability and use of oxygen support options in low-income and middle-income countries are highly variable but appear significantly less in the African region. Mortality might be associated with a lack of access to oxygen, which varied across WHO regions but was highest in Africa. Despite many lessons learned from the COVID-19 pandemic, inequity in access to medical oxygen remains a challenge that WHO and partners must address in the post-pandemic era to avoid preventable deaths.FUNDINGUNITAID.","PeriodicalId":48783,"journal":{"name":"Lancet Global Health","volume":"46 1","pages":"e233-e241"},"PeriodicalIF":34.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145947456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/s2214-109x(25)00530-3
T V Sekher,David Flood,Peifeng Hu,Mohammed K Ali,Ashwini Shete,Sarang Pedgaonkar,Kenneth M Langa,Eileen M Crimmins,David E Bloom,Jinkook Lee
{"title":"HbA1c alone might not reliably indicate India's diabetes prevalence - Authors' reply.","authors":"T V Sekher,David Flood,Peifeng Hu,Mohammed K Ali,Ashwini Shete,Sarang Pedgaonkar,Kenneth M Langa,Eileen M Crimmins,David E Bloom,Jinkook Lee","doi":"10.1016/s2214-109x(25)00530-3","DOIUrl":"https://doi.org/10.1016/s2214-109x(25)00530-3","url":null,"abstract":"","PeriodicalId":48783,"journal":{"name":"Lancet Global Health","volume":"48 1","pages":"e196"},"PeriodicalIF":34.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145947462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/s2214-109x(25)00440-1
Aleya Khalifa,Debbie E Malden,Oliver Ratmann,Yu Chen,M Kate Grabowski,Larry W Chang,Fred Nalugoda,Godfrey Kigozi,Tom Lutalo,Nelson K Sewankambo,Anthony Ndyanabo,Philip Kreniske,Fredrick Makumbi,David Serwadda,Robert Ssekubugu,Absalom Ssettuba,Hadijja Nakawooya,Susan Hillis,John S Santelli
BACKGROUNDThe introduction and scale-up of HIV treatment and prevention programmes have resulted in steady declines in orphanhood prevalence in sub-Saharan Africa, but orphanhood incidence and its associated factors are less understood. We aimed to describe the incidence and prevalence of orphanhood after HIV treatment and prevention programmes became available in Rakai, Uganda.METHODSIn this population-based cohort study, we used data from all children and adolescents younger than 18 years with censused parents residing in 28 continuously surveyed Rakai Community Cohort Study (RCCS) communities from 1995 to 2022 (N=92 441), to calculate maternal, paternal, and double orphanhood prevalence by census round. Orphanhood incidence was estimated by use of a non-parametric hierarchical Bayesian model over time among children whose parents were alive during their first census interview and who were censused at least twice without missing more than two consecutive census visits (N=54 411). Poisson regression models estimated incidence rate ratios of orphanhood and 95% CIs by time period (pre-antiretroviral therapy [ART; 1995-2003], ART partial availability [2004-14], and ART full availability [2015-22]), age at orphanhood, and socioeconomic status of the household. Population attributable fractions of incident orphanhood due to parents' HIV-positive status were estimated among those with surveyed parents who were tested for HIV.FINDINGSOrphanhood prevalence declined considerably over the study period, with steepest declines after ART became available; from 21·5% (3421 of 15 941 individuals) in 2003-04 to 6·3% (1449 of 23 082 individuals) in 2020-22. In adolescents aged 15-17 years, orphanhood prevalence declined from 49·4% (1057 of 2138) in 2002-03 to 14·4% (526 of 3661 individuals) in 2020-22. Incidence rates declined sharply; double orphanhood declined from 5·13 (95% CI 4·02-6·45) per 1000 person-years in 2003-04 to 0·68 (0·42-1·05) per 1000 person-years in 2020-22. The proportion of new cases of orphanhood attributed to parental HIV status declined from 67% in 2004 to 11% in 2022 for paternal orphanhood and from 71% to 12% for maternal orphanhood.INTERPRETATIONScale-up of ART in this Ugandan setting drove substantive declines in orphanhood incidence. Yet, a considerable burden of orphanhood persisted in 2022, particularly among adolescents. To consolidate these gains, sustained investment and adaptation of HIV programmes are crucial to mitigate the ongoing risk of orphanhood for this vulnerable population.FUNDINGNational Institute of Allergy and Infectious Diseases, National Institute of Child Health and Development, Gates Foundation, National Institute of Mental Health, and National Institutes of Health Fogarty International Center.
{"title":"Incidence and prevalence of orphanhood in Rakai, Uganda: a population-based cohort study, 1995-2022.","authors":"Aleya Khalifa,Debbie E Malden,Oliver Ratmann,Yu Chen,M Kate Grabowski,Larry W Chang,Fred Nalugoda,Godfrey Kigozi,Tom Lutalo,Nelson K Sewankambo,Anthony Ndyanabo,Philip Kreniske,Fredrick Makumbi,David Serwadda,Robert Ssekubugu,Absalom Ssettuba,Hadijja Nakawooya,Susan Hillis,John S Santelli","doi":"10.1016/s2214-109x(25)00440-1","DOIUrl":"https://doi.org/10.1016/s2214-109x(25)00440-1","url":null,"abstract":"BACKGROUNDThe introduction and scale-up of HIV treatment and prevention programmes have resulted in steady declines in orphanhood prevalence in sub-Saharan Africa, but orphanhood incidence and its associated factors are less understood. We aimed to describe the incidence and prevalence of orphanhood after HIV treatment and prevention programmes became available in Rakai, Uganda.METHODSIn this population-based cohort study, we used data from all children and adolescents younger than 18 years with censused parents residing in 28 continuously surveyed Rakai Community Cohort Study (RCCS) communities from 1995 to 2022 (N=92 441), to calculate maternal, paternal, and double orphanhood prevalence by census round. Orphanhood incidence was estimated by use of a non-parametric hierarchical Bayesian model over time among children whose parents were alive during their first census interview and who were censused at least twice without missing more than two consecutive census visits (N=54 411). Poisson regression models estimated incidence rate ratios of orphanhood and 95% CIs by time period (pre-antiretroviral therapy [ART; 1995-2003], ART partial availability [2004-14], and ART full availability [2015-22]), age at orphanhood, and socioeconomic status of the household. Population attributable fractions of incident orphanhood due to parents' HIV-positive status were estimated among those with surveyed parents who were tested for HIV.FINDINGSOrphanhood prevalence declined considerably over the study period, with steepest declines after ART became available; from 21·5% (3421 of 15 941 individuals) in 2003-04 to 6·3% (1449 of 23 082 individuals) in 2020-22. In adolescents aged 15-17 years, orphanhood prevalence declined from 49·4% (1057 of 2138) in 2002-03 to 14·4% (526 of 3661 individuals) in 2020-22. Incidence rates declined sharply; double orphanhood declined from 5·13 (95% CI 4·02-6·45) per 1000 person-years in 2003-04 to 0·68 (0·42-1·05) per 1000 person-years in 2020-22. The proportion of new cases of orphanhood attributed to parental HIV status declined from 67% in 2004 to 11% in 2022 for paternal orphanhood and from 71% to 12% for maternal orphanhood.INTERPRETATIONScale-up of ART in this Ugandan setting drove substantive declines in orphanhood incidence. Yet, a considerable burden of orphanhood persisted in 2022, particularly among adolescents. To consolidate these gains, sustained investment and adaptation of HIV programmes are crucial to mitigate the ongoing risk of orphanhood for this vulnerable population.FUNDINGNational Institute of Allergy and Infectious Diseases, National Institute of Child Health and Development, Gates Foundation, National Institute of Mental Health, and National Institutes of Health Fogarty International Center.","PeriodicalId":48783,"journal":{"name":"Lancet Global Health","volume":"37 1","pages":"e251-e260"},"PeriodicalIF":34.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145947454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BACKGROUNDAccording to WHO and UNICEF, Africa has the lowest coverage (18%) of timely (within the first 24 h) hepatitis B birth dose (HepB-BD) vaccination worldwide. To eliminate hepatitis B by 2030, 90% vaccination coverage is required. Experiences from The Gambia, the first African country to adopt HepB-BD vaccination in 1990, could guide HepB-BD implementation and scale-up in Africa. We aimed to assess the trend of, and barriers to, timely HepB-BD vaccination coverage over a 7-year period in The Gambia.METHODSIn this retrospective analysis, 2015-21 data were extracted from population-based Health and Demographic Surveillance Systems in three rural areas (Basse, Bansang, and Farafenni) in The Gambia. Fluctuation tests and Bayesian analysis using Markov chain Monte Carlo methods assessed the rate of timely (within days 0-1 of birth) and delayed HepB-BD vaccination coverage, change points (abrupt variation between two stable periods) in the average coverage of timely HepB-BD vaccination, and the factors associated with delayed HepB-BD vaccination during the first 7 years following the WHO recommendations on hepatitis B elimination.FINDINGSBetween Jan 1, 2015, and Dec 31, 2021, 4560 of 71 088 livebirths (6·4%, 95% CI 6·2-6·6) received a timely HepB-BD. Timely HepB-BD vaccination coverage increased from 1·7% (95% CI 1·3-2·0) in the first half of 2015 (ie, January to June) to 22·4% (21·3-23·6) in the second half of 2021 (ie, July to December; p<0·0001). Delayed HepB-BD administration was associated with being born on Friday (odds ratio [OR] 3·51 [95% CI 3·03-4·08]; p<0·0001) or Saturday (5·93 [4·96-7·13]; p<0·0001) compared with Tuesday; being born in Basse (2·03 [95% CI 1·83-2·25]; p<0·0001) or Farafenni (1·84 [1·63-2·08]; p<0·0001); and being born during the rainy season (1·16 [1·08-1·25]; p<0·0001). Average timely HepB-BD vaccination coverage significantly decreased from 10·1% (95% CI 9·5-10·6) pre-COVID-19 pandemic to 5·4% (4·5-6·3) during the first COVID-19 wave (p<0·0001). After adjusting for all other factors, being born during the first COVID-19 wave was associated with delayed HepB-BD vaccination (OR 1·41 [1·22-1·64]; p<0·0001).INTERPRETATION30 years after the adoption of HepB-BD in The Gambia, the rate of vaccination coverage remains low and was significantly affected by the COVID-19 pandemic, highlighting the challenges for its implementation.FUNDINGNone.
根据世卫组织和联合国儿童基金会的数据，非洲在世界范围内及时（在最初24小时内）接种乙型肝炎出生疫苗的覆盖率（18%）最低。为了到2030年消除乙型肝炎，需要90%的疫苗接种覆盖率。冈比亚是1990年第一个采用乙型肝炎疫苗接种的非洲国家，其经验可以指导乙型肝炎疫苗在非洲的实施和推广。我们的目的是评估冈比亚7年期间乙肝- bd疫苗及时覆盖的趋势和障碍。方法回顾性分析2015-21年冈比亚三个农村地区（Basse、Bansang和Farafenni）基于人口的健康和人口监测系统的数据。使用马尔科夫链蒙特卡罗方法的波动试验和贝叶斯分析评估了及时（出生后0-1天内）和延迟乙肝疫苗接种覆盖率，平均及时乙肝疫苗接种覆盖率的变化点（两个稳定时期之间的突变），以及在世卫组织建议消除乙肝后的前7年内延迟乙肝疫苗接种的相关因素。结果：2015年1月1日至2021年12月31日期间，71,088例活产婴儿中有4560例（6.4%,95% CI 6.2 - 6.6）及时接受了HepB-BD治疗。乙肝疫苗的及时接种率从2015年上半年（即1月至6月）的1.7% （95% CI 1·3-2·0）增加到2021年下半年（即7月至12月，p< 0.0001）的22.4%（21·3-23·6）。与周二相比，延迟给药与出生在周五（比值比[OR] 3.51 [95% CI 3.03 -4·08],p< 0.0001）或周六（比值比[5.93 [4.96 - 7.13],p< 0.0001）相关；出生在Basse （2.03 [95% CI 1.83 - 2.25], p< 0.0001）或Farafenni (1.84 [1.63 - 2.08], p< 0.0001)；在雨季出生（1.16 [1.08 - 1.25];p< 0.0001）。平均及时HepB-BD疫苗接种率从COVID-19大流行前的10.1% （95% CI 9.5 - 10.6）显著下降到第一波COVID-19期间的5.4% (4.5 - 6.3)（p< 0.0001）。在对所有其他因素进行调整后，在第一次COVID-19浪潮期间出生与延迟接种HepB-BD相关（OR为1.41[1.22 -1·64];p< 0.0001）。在冈比亚采用乙型肝炎疫苗接种30年后，疫苗接种率仍然很低，并受到COVID-19大流行的严重影响，这凸显了实施该疫苗接种所面临的挑战。
{"title":"7-year trend of timely hepatitis B birth dose vaccination coverage in The Gambia: a retrospective, population-based analysis.","authors":"Gibril Ndow,Isatou Cham,Rohey Bangura,Sainabou Drammeh,Cecile de Bezenac,Sarwar Golam S,Esu Ezeani,Pierre Gomez,Sheriff Badjie,Sidat Fofana,Mustapha Bittaye,Grant Mackenzie,Julien Randon-Furling,Umberto D'Alessandro,Yusuke Shimakawa,Maud Lemoine","doi":"10.1016/s2214-109x(25)00270-0","DOIUrl":"https://doi.org/10.1016/s2214-109x(25)00270-0","url":null,"abstract":"BACKGROUNDAccording to WHO and UNICEF, Africa has the lowest coverage (18%) of timely (within the first 24 h) hepatitis B birth dose (HepB-BD) vaccination worldwide. To eliminate hepatitis B by 2030, 90% vaccination coverage is required. Experiences from The Gambia, the first African country to adopt HepB-BD vaccination in 1990, could guide HepB-BD implementation and scale-up in Africa. We aimed to assess the trend of, and barriers to, timely HepB-BD vaccination coverage over a 7-year period in The Gambia.METHODSIn this retrospective analysis, 2015-21 data were extracted from population-based Health and Demographic Surveillance Systems in three rural areas (Basse, Bansang, and Farafenni) in The Gambia. Fluctuation tests and Bayesian analysis using Markov chain Monte Carlo methods assessed the rate of timely (within days 0-1 of birth) and delayed HepB-BD vaccination coverage, change points (abrupt variation between two stable periods) in the average coverage of timely HepB-BD vaccination, and the factors associated with delayed HepB-BD vaccination during the first 7 years following the WHO recommendations on hepatitis B elimination.FINDINGSBetween Jan 1, 2015, and Dec 31, 2021, 4560 of 71 088 livebirths (6·4%, 95% CI 6·2-6·6) received a timely HepB-BD. Timely HepB-BD vaccination coverage increased from 1·7% (95% CI 1·3-2·0) in the first half of 2015 (ie, January to June) to 22·4% (21·3-23·6) in the second half of 2021 (ie, July to December; p<0·0001). Delayed HepB-BD administration was associated with being born on Friday (odds ratio [OR] 3·51 [95% CI 3·03-4·08]; p<0·0001) or Saturday (5·93 [4·96-7·13]; p<0·0001) compared with Tuesday; being born in Basse (2·03 [95% CI 1·83-2·25]; p<0·0001) or Farafenni (1·84 [1·63-2·08]; p<0·0001); and being born during the rainy season (1·16 [1·08-1·25]; p<0·0001). Average timely HepB-BD vaccination coverage significantly decreased from 10·1% (95% CI 9·5-10·6) pre-COVID-19 pandemic to 5·4% (4·5-6·3) during the first COVID-19 wave (p<0·0001). After adjusting for all other factors, being born during the first COVID-19 wave was associated with delayed HepB-BD vaccination (OR 1·41 [1·22-1·64]; p<0·0001).INTERPRETATION30 years after the adoption of HepB-BD in The Gambia, the rate of vaccination coverage remains low and was significantly affected by the COVID-19 pandemic, highlighting the challenges for its implementation.FUNDINGNone.","PeriodicalId":48783,"journal":{"name":"Lancet Global Health","volume":"262 1","pages":"e242-e250"},"PeriodicalIF":34.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145947458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-30DOI: 10.1016/s2214-109x(26)00020-3
Marta Ribes, Claudia García-Vaz, Carlos Chaccour, Eldo Elobolobo, Larraitz Ventoso, Anna Roca, Anna Dimitrova
{"title":"Converging global crises and the re-emergence of neglected tropical diseases: the case of noma","authors":"Marta Ribes, Claudia García-Vaz, Carlos Chaccour, Eldo Elobolobo, Larraitz Ventoso, Anna Roca, Anna Dimitrova","doi":"10.1016/s2214-109x(26)00020-3","DOIUrl":"https://doi.org/10.1016/s2214-109x(26)00020-3","url":null,"abstract":"","PeriodicalId":48783,"journal":{"name":"Lancet Global Health","volume":"44 1","pages":""},"PeriodicalIF":34.3,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146089575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-27DOI: 10.1016/s2214-109x(26)00025-2
{"title":"Correction to Lancet Glob Health 2025; 13: e1869–79","authors":"","doi":"10.1016/s2214-109x(26)00025-2","DOIUrl":"https://doi.org/10.1016/s2214-109x(26)00025-2","url":null,"abstract":"","PeriodicalId":48783,"journal":{"name":"Lancet Global Health","volume":"4 1","pages":""},"PeriodicalIF":34.3,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146071472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-16DOI: 10.1016/s2214-109x(26)00007-0
{"title":"Correction to Lancet Glob Health 2026; 14: e4–5","authors":"","doi":"10.1016/s2214-109x(26)00007-0","DOIUrl":"https://doi.org/10.1016/s2214-109x(26)00007-0","url":null,"abstract":"","PeriodicalId":48783,"journal":{"name":"Lancet Global Health","volume":"39 1","pages":""},"PeriodicalIF":34.3,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145995283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-16DOI: 10.1016/s2214-109x(26)00004-5
Victoire Fokom Defo, Joël Fokom Domgue
{"title":"Understanding the WHO global strategy to accelerate cervical cancer elimination","authors":"Victoire Fokom Defo, Joël Fokom Domgue","doi":"10.1016/s2214-109x(26)00004-5","DOIUrl":"https://doi.org/10.1016/s2214-109x(26)00004-5","url":null,"abstract":"","PeriodicalId":48783,"journal":{"name":"Lancet Global Health","volume":"16 1","pages":""},"PeriodicalIF":34.3,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145995284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：